Senomyx Appoints Mary Ann Gray to Board of Directors
Mary Ann Gray, Ph.D., is currently President of Gray Strategic Advisors, LLC, which provides strategic consulting services to the biotechnology industry. Dr. Gray also serves on the Boards of Directors of Dyax Corp. and Acadia Pharmaceuticals.
Sep 29 2010 --- Senomyx, Inc., a leading company focused on using proprietary taste receptor technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, has announced that Mary Ann Gray, Ph.D., has joined the Company’s Board of Directors. Dr. Gray has extensive experience in both the financial community and the biotechnology industry.
“Mary Ann Gray has a strong background as an equity research analyst, strategic advisor, scientist, and member of Boards of Directors of public companies,” said Kent Snyder, President, Chief Executive Officer, and Chairman of the Board of the Company. “We believe Senomyx will benefit from her insights and expertise as we continue to advance our discovery and development programs and enter into new collaborations with world-class food, beverage, and ingredient supply company partners.”
Mary Ann Gray, Ph.D., is currently President of Gray Strategic Advisors, LLC, which provides strategic consulting services to the biotechnology industry. Dr. Gray also serves on the Boards of Directors of Dyax Corp. and Acadia Pharmaceuticals, both publicly-held companies, and Apthera Inc., a privately held company. She is the Chairman of the Audit Committee and a member of the Compensation Committee at Acadia, and Lead Director and a member of the Audit Committee at Dyax. During the past five years, Dr. Gray also served on the Boards of Directors of two additional public companies. From 1999 to 2003, Dr. Gray was Senior Analyst and Portfolio Manager for the Federated Kaufmann Fund. Prior to 1999, Dr. Gray led biotechnology equity research groups at Raymond James & Associates, Warburg Dillon Read, and Kidder Peabody for an aggregate of nine years. Dr. Gray holds a Ph.D. degree in pharmacology from the University of Vermont, where she focused on novel chemotherapeutic agents for the treatment of cancer.
